Quest Partners LLC Acquires 9,739 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Quest Partners LLC boosted its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 15,965.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 9,800 shares of the company’s stock after acquiring an additional 9,739 shares during the period. Quest Partners LLC’s holdings in OptimizeRx were worth $76,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Light Asset Management LLC grew its stake in shares of OptimizeRx by 5.1% in the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after acquiring an additional 89,377 shares during the period. Vanguard Group Inc. boosted its holdings in OptimizeRx by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after purchasing an additional 6,291 shares during the last quarter. Rice Hall James & Associates LLC grew its position in OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after purchasing an additional 119,306 shares during the period. Dimensional Fund Advisors LP raised its stake in OptimizeRx by 12.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock valued at $3,241,000 after buying an additional 35,957 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its holdings in shares of OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock valued at $1,868,000 after buying an additional 72,672 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Up 2.3 %

OPRX stock opened at $5.45 on Friday. The business’s 50-day moving average price is $6.03 and its 200-day moving average price is $8.58. The stock has a market cap of $100.39 million, a P/E ratio of -4.10 and a beta of 1.32. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $16.65.

Analysts Set New Price Targets

OPRX has been the subject of several research analyst reports. Royal Bank of Canada cut their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Barclays dropped their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. Stifel Nicolaus reduced their price target on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. JMP Securities lowered their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. Finally, Roth Mkm restated a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, OptimizeRx has a consensus rating of “Moderate Buy” and an average price target of $10.42.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.